Clinical Trials Logo

Candidiasis clinical trials

View clinical trials related to Candidiasis.

Filter by:

NCT ID: NCT03987620 Completed - Clinical trials for Candida Vulvovaginitis

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Vanish 306
Start date: June 7, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.

NCT ID: NCT03975569 Completed - Clinical trials for Candidiasis, Vulvovaginal

Study of the Vaginal Microbiota and the Potential of a Vaginal Probiotic Cream in Vaginal Candidosis

Start date: April 4, 2016
Phase: N/A
Study type: Interventional

This study evaluated the effect of a vaginal gel containing three live probiotic bacteria on vaginal Candida albicans infection in flemish patients (n=20). The therapeutic effects of the gel will be clinically evaluated (vaginal pH, microscopic and clinical scores). The effect on the vaginal microbiome will be evaluated through 16S ribosomal RNA amplicon sequencing via MiSeq Illumina and polymerase chain reaction (PCR) for Candida albicans.

NCT ID: NCT03940612 Completed - Vaginal Diseases Clinical Trials

Probiotic for Vaginal Candidiasis in Pregnant Women

Start date: June 16, 2019
Phase: N/A
Study type: Interventional

This project aims to study the benefits of a probiotic product, STP4 for vaginal health properties, primarily prevention of vaginal candidiasis, among pregnant women in second and third trimester pregnancy.

NCT ID: NCT03894839 Completed - Candidiasis, Oral Clinical Trials

Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species

Start date: October 26, 2017
Phase: N/A
Study type: Interventional

Individuals may experience tooth loss as a result of trauma, periodontal destruction, lack of adequate bone support and clinically dental mobility. The increase in these tooth loss results in a condition called complete toothlessness in patients, and as a result of this, dentists treat complete dentures. It is known that the microorganism retention in the existing restorations is faster and higher than the natural tissues, and this leads to faster plaque build-up and hence bad odor. Candida species are common in oral flora, because they are numerous in the mouth and they are opportunistic pathogenic fungi that can make superficial and deep infections. The most important pathogen species among these parasites is Candida albicans. Mouth moniliasis or acute pseudomembrane candidiasis in the oral cavity of the so-called canker is caused by C.albicans. Chronic hyperplastic candidiasis is a clinical entity that is clinically inseparable from leukoplakia and completely separate from thrush. The accumulation of microorganisms in prosthetic materials is very important for the protection of the health of oral tissues and it is desirable to use appropriate cleaning and disinfection materials to minimize this accumulation. It is known in the literature that ozone and microwave technologies are used as disinfection technique. In this study, the application of ozone and microwave technologies in addition to the cleaning agents used as standard treatment will be compared in vivo. No such research has been found.The aim of this study was to evaluate the effect of different cleaning and disinfection procedures on the involvement of Candida species in complete denture patients.

NCT ID: NCT03840616 Completed - Clinical trials for Recurrent Vulvovaginal Candidiasis

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

ultraVIOLET
Start date: March 13, 2019
Phase: Phase 3
Study type: Interventional

Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute vulvovaginal candidiasis (VVC) in the past 12 months. Several properties of oteseconazole (VT-1161) suggest it might be a safer and more effective treatment of RVVC than other oral antifungal medications. This study will evaluate the effectiveness and safety of oteseconazole (VT-1161) for the treatment of acute VVC episodes in patients with RVVC and consists of 2 parts. The first part of the study is a 2-week induction phase for the treatment of the patient's current VVC episode when the patient will take either fluconazole or oteseconazole (VT-1161) according to a random assignment. The second part consists of an 11-week maintenance phase, when the patient will take either oteseconazole (VT-1161) or a placebo according to the random assignment from the first part of the study, and then a 37-week follow-up period.

NCT ID: NCT03761628 Completed - Clinical trials for Vulvovaginal Candidiasis

Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis

Start date: January 7, 2019
Phase: N/A
Study type: Interventional

This is an open-label, single-armed, multi-center study to evaluate clinical performance, tolerability, and safety of Gedea Pessary in 24 adult women with VVC. On Day 0, patients will have gynecological examination, vaginal samples taken, and will receive the investigational product to be self-administered. Patients will be examined after 7 days with respect to VVC signs and symptoms and if not cured, will receive prolonged treatment for one additional week. Patients will be followed-up by telephone up to 29 days after last treatment. Vaginal samples will be used for confirming diagnosis and microbiome analyzes. Patient questionnaires will be used for assessing VVC symptoms, usability, and adverse events (AEs).

NCT ID: NCT03734991 Completed - Clinical trials for Candida Vulvovaginitis

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Start date: January 4, 2019
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.

NCT ID: NCT03667690 Completed - Fungal Infection Clinical Trials

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

ReSTORE
Start date: October 7, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

NCT ID: NCT03641131 Completed - Fungal Infection Clinical Trials

Ampholipad Real-World Data in Taiwan

Start date: September 9, 2018
Phase:
Study type: Observational

A retrospective, post-marketing, multi-center chart review study includes patients who had been prescribed Ampholipad.

NCT ID: NCT03630770 Completed - Premature Infant Clinical Trials

Effect of Medium Chain Triglyceride Intake on Colonization of Preterm Infants With Candida

Start date: June 5, 2014
Phase: Phase 1
Study type: Interventional

This study evaluates whether adding a dietary supplement similar to coconut oil (MCT oil) to feedings in premature infants will reduce the amount of yeast (Candida) detectable in their stool. Infants who have Candida in their stool are eligible to participate. Half of the enrolled infants will have additional MCT oil added to their feedings and half will not.